IO Biotech Reports First Patient Dosing of IO102-IO103 + Keytruda (pembrolizumab) in the P-III (IOB-013 / KN-D18) Trial as 1L Treatment of Advanced Melanoma
Shots:
- The 1st patient has been dosed in the P-III (IOB-013/KN-D18) trial to evaluate IO102-IO103 + pembrolizumab vs pembrolizumab alone in 300 patients with prior untreated, unresectable, or MM across the US, Australia & EU. IO will sponsor the trial & maintains global commercial rights to IO102-IO103 while Merck will supply pembrolizumab
- In a P-I/II trial, the combination therapy induced tumor regression & established durable antitumor response with a manageable tolerability profile, ORR (80%), CR rate (43%), grade 3-4 AEs (13%) of patients
- IO102-IO103 are the immune-modulatory vaccines targeting IDO & PD-L1. The therapy has received BTD from the US FDA for MM, based on the P-I/II trial results
Ref: Globenewswire | Image: IO Biotech
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
